New quality concepts in pharmaceuticals

Year 2014, Volume: 4 Issue: 2, 96 - 104, 15.12.2014

Buket Aksu , Gizem Yeğen

Abstract

During the recent years, the pharmaceutical industry, trying to adapt itself to innovations by leaps and bounds, has experienced major developments in production information, quality management systems and risk management, and has developed modern production tools that can assist in ensuring the production quality. These new tools help the manufacturers identify, analyze, correct and prevent problems, and constantly enhance the production processes. Therefore, in 2002, the Food and Drug Administration (FDA) introduced to the drug pharmaceutical industry the amendments in the current Good Manufacturing Practices (cGMP) to improve and modernize the rules that regulate the pharmaceutical product manufacturing and the pharmaceutical product quality. International Conference on Harmonization (ICH) is a forum that gathers the authorities and experts of the pharmaceutical industry in the USA, Japan and Europe to harmonize the technical requirements for pharmaceutical products in these three regions, published current guidelines (ICH Q8, Q9, Q10 and Q11) to bring a new approach which called Quality by Design (QbD) to the industry. As a result of using the new approach of providing quality by design rather than testing it, quality increase, cost reduction and faster market access have been achieved in manufactured products. Moreover, patient safety is emphasized and quicker access to pharmaceutical products by the patient is ensured with a higher quality products.

Keywords

-

Farmasötiklerde yeni kalite kavramları

Abstract

Büyük hızla yeniliklere adapte olmaya çalışan ilaç sanayii, son yıllarda, üretim bilgilerinde, kalite yönetim sistemlerinde ve risk yönetiminde önemli ilerlemeler yaşamış ve üretim kalitesinin sağlanmasına yardımcı olmak için kullanılabilecek modern üretim araçları geliştirmiştir. Bu yeni araçlar üreticilerin problemleri saptamasına, analiz etmesine, düzeltmesine, önlemesine ve üretim süreçlerini sürekli olarak iyileştirmesine yardım etmektedir. Bu gelişmeler üzerine, 2002 yılında Amerikan Gıda ve İlaç Dairesi (FDA), ilaç üretimini düzenleyen kuralları ve ürün kalitesini daha da geliştirmek ve modernize etmek amacı ile Güncel İyi Üretim Uygulamalarındaki (cGMP) yenilikleri ilaç endüstrisine duyurmuştur. ABD, Japonya ve Avrupa’da ilaç endüstrisinin yetkilileri ve uzmanlardan oluşan, ilaç ürünleri için teknik gereksinimlerin bu üç bölgede uyumlaştırılması amacıyla kurulmuş bir forum olan Uluslararası Harmonizasyon Kurumu (ICH), endüstriye Tasarımla Kalite (QbD) olarak adlandırılan yeni bir yaklaşım getirmek için güncel kılavuzları (ICH Q8, Q9, Q10 ve Q11) yayınlamıştır. Kaliteyi test etmek yerine tasarımla sağlayan bu yeni yaklaşımın bir sonucu olarak, üründe kalite artışı, üretim maliyetinde azalma ve ürünün piyasaya daha kısa sürede sunulması sağlanmaktadır. Ayrıca, hastanın güvenliği ve daha kaliteli ilaca daha kısa sürede ulaşması üzerinde durulmaktadır.

Keywords

Üretim Kalitesi, ICH, Tasarımla kalite

References

• Refoios Camejo R, McGrath C, Herings, R. A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness. Health Policy. 2011;100(1):18-24.
• Aksu B, Paradkar A, de Matas M, Özer Ö, Güneri T, York P. Quality by Design Approach: Application of Artificial Intelligence Techniques of Tablets Manufactured by Direct Compression. AAPS Pharm Sci Tech. 2012;13(4):1138-1146.
• FDA. Pharmaceutical cGMPs for the 21st Century - A Risk-Based Approach. Silver Spring: FDA; 2004.
• ich.org [Internet]. [cited: 2012 Apr 20]. Available form: http://www. ich.org/.
• ICH. Pharmaceutical Development Q8(R2) (Step 4). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 2009.
• ICH. Quality Risk Management (Q9) (Step 4). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005.
• ICH. Pharmaceutical Quality System (Q10) (Step 4). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2008.
• ICH. Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (Q11) (Step 3). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2012.
• Cogdill RP. Case for Process Analytical Technology: Regulatory and Industrial Perspectives. In: Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing. John Wiley & Sons Inc; 2010. p.313-352.
• CDER. Guidance for Industry: Comparability Protocols —Chemistry, Manufacturing, and Controls Information. FDA; 2003.
• Arling ER, Dowling ME, Frankel PA. Process Analytical Technology. In Gad SC, eds. Pharmaceutical Manufacturing Handbook: Regulations and Quality. New York: John Wiley&Sons, Inc; 2008. p.353-410
• CDER. PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA; 2004.
• Mhatre R, Rathore AS. Quality by Design: An Overview of the Basic Concepts. In: Rathore AS, Mhatre R, eds. Quality by Design for Biopharmaceuticals: Principles and Case Studies. NJ, Hoboken: John Wiley & Sons, Inc; 2008. p.1-7.
• Singh SK, Venkateshwaran TG & Simmons SP. Oral Controlled Drug Delivery: Quality by Design (QbD) Approach to Drug Development. In: Wen H, Park K, eds. Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. NJ, Hoboken: John Wiley & Sons, Inc; 2010. p.279-303.
• CDER. Guidance for Industry and Review Staff Target Product Profile - A Strategic Development Process Tool. FDA; 2007.
• Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by Design: Concepts for ANDAs. AAPS J. 2008; 10(2): 268-276.
• Aksu, B. İlaçta Kalite Tasarımı (QbD) ve İlgili Yasal Düzenlemeler. İstanbul: Neta Reklam Tanıtım Matbaacılık San. Tic. Ltd. Şti; 2013.
• Short SM, Cogdill RP, Drennen III JK, Anderson CA. Performance- based quality specifications: The relationship between process critical control parameters, critical quality attributes, and clinical performance. J Pharm Sci. 2010; 100(4): 1566-1575.
• Lepore J, Spavins J. PQLI Design Space. J Pharm Innov. 2008; 3 (2): 79-87.
• Aksu B, Paradkar A, de Matas M, Özer Ö, Güneri T, York P. A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation. Pharm Dev Technol. 2013; 18 (1): 236-245.
• Garcia T, Cook G, Nosal R. PQLI Key Topics - Criticality, Design Space, and Control Strategy. J Pharm Innov. 2008; 3:60-68.
• Schmitt S. Quality by Design Putting Theory into Practice. LLC, USA: Davis Healthcare International Publishing; 2011.
• ISPE. Part 1- Product Realization using Quality by Design (QbD): Concepts and Principles. ISPE Guide Series: PQLI from Concept to Continual Improvement. Florida: ISPE; 2011.
• Fda.gov [Internet]. Nasr MM. FDA. [2011 July 27; Retrieved 2013 Aug 20]. Available from: http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/Advisory CommitteeforPharmaceuticalScienceandClinicalPharmacology/ UCM266751.pdf
• Diahome.org [Internet]. Chen CW. Beijing: Major Regulators’ Perspectives on Quality-by-Design (QbD) Implementation. [2011 May 15; Retrieved 2013 June 10]. Available from: http://www.diahome. org/productfiles/25849/20110517/track4/07%20t4-3_chen%20chi- wan.pptx
• Fwc.com [Internet]. Thomas H. FWC. [2005 July; Retrieved 2013 April 20]. Available from: https://www.fwc.com/publications/pdf/ Article_LeanMfg_FOCUS.pdf